Patent echoes for Viralytics
Monday, 30 March, 2009
Sydney company Viralytics has received a patent in the US for its range of echoviruses, which aim to bind to and infect cancer cells.
The echovirus type 1 (EV1) binds to cells expressing integrin alpha2 beta 2, a receptor on the cell surface receptor highly expressed in some cancers, particularly prostate, ovarian and gastric tumours.
Viralytics has a proprietary formulation of EV1 called Evatak, as well as a formulation for a subset of coxsackie A viruses called Cavatak. Cavatak binds to the receptors intercellular adhesion molecule-1 and decay accelerating factor.
The company is running Phase I trials of Cavatak in melanoma, prostate, breast and head and neck cancers.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
